Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9234355 | 0.86 | DAO (0.45) | DAONAPRTAURKAAURKBINCENP | |
| SCHEMBL8712639 | 0.81 | DAO (0.41) | DAONAPRTAURKAAURKBINCENP | |
| SCHEMBL10692239 | 0.81 | DAO (0.41) | DAONAPRTAURKAAURKBINCENP | |
| SCHEMBL4602524 | 0.81 | CHEK1 (0.51) | DAONAPRTAURKAAURKBINCENP | |
| SCHEMBL217278 | 0.79 | — | — | |
| SCHEMBL2495417 | 0.79 | GPR84 (0.46) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL14974903 | 0.78 | GPR84 (0.49) | MCL1KDM4ETHRB | |
| SCHEMBL10764266 | 0.78 | GPR84 (0.49) | MCL1KDM4ETHRB | |
| SCHEMBL16057325 | 0.78 | DAO (0.46) | DAOMCL1 | |
| SCHEMBL5166986 | 0.78 | GPR84 (0.49) | MCL1KDM4ETHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108017577-A | The process for catalytic synthesis of 2- pyridones | 怀化学院 | 2018-05-11 | — | — | CN | disclosed |
| US-6696552-B2 | AMIDATION BETWEEN PRIMARY AMINE AND ESTER HAVING ELECTRON WITHDRAWING FUNCTIONALITY; CYCLIZATION WITH KETO ESTER | XEROX CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-20040006234-A1 | PROCESS FOR PREPARING SUBSTITUTED PYRIDONE COMPOUNDS | XEROX CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6673139-B1 | Phase change inks containing dimeric azo pyridone colorants | XEROX CORPORATION | 2004-01-06 | — | — | US | disclosed |
| US-6646111-B1 | Phase change inks | XEROX CORPORATION | 2003-11-11 | — | — | US | disclosed |
| US-6576748-B1 | Diazotizing dianiline compound; salt formation, coupling, desalting; reaction with pyridone or dipyridone compound | XEROX CORPORATION | 2003-06-10 | — | — | US | disclosed |
| EP-0873319-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-10-28 | — | — | EP | disclosed |
| EP-0858451-A1 | PHARMACEUTICALLY ACTIVE QUINAZOLINE COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997022596-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-06-26 | — | — | WO | disclosed |
| WO-1997014686-A1 | PHARMACEUTICALLY ACTIVE QUINAZOLINE COMPOUNDS | ASTRA PHARMACEUTICALS LIMITED (GB) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006234-A1 | PROCESS FOR PREPARING SUBSTITUTED PYRIDONE COMPOUNDS | PDXK, DPYD, RRM2B | DAO 2287/4885NAPRT 852/4885AURKA 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.